GLP-1s and Eye Health with Dr. Andrea Tooley
Wise EYES Guys Podcast — Episode 6
What would you do if you woke up with a dark patch in one eye and felt no pain? It’s one of the scenarios the Wise EYES Guys bring to Dr. Andrea Tooley in an episode about GLP-1 medications and eye health.
Dr. Andrew Holzman, Dr. Jonathan Solomon, and Dr. Sonny Goel welcome Dr. Tooley, an ophthalmologist who specializes in surgery of the eyelids and eye socket. The conversation starts with the FDA’s November 2026 safety communication about a potential increased risk of a rare optic nerve condition called NAION. It then turns to two other questions patients may bring to an eye exam: how a rapid change in blood sugar can affect existing diabetic eye disease, and what can happen around the eyelids after significant weight loss.
In This Episode
- What NAION is and how a missing patch of vision might show up in daily life
- Why someone can still read an eye chart with part of their field of vision missing
- How common NAION was in the trials the FDA reviewed
- Why it’s hard to estimate risk for a specific medication or patient
- What to do if you suddenly lose vision in one eye
- What to ask your eye doctor and prescriber if you’ve previously had NAION
- Why your last eye exam and recent A1c matter if you have diabetic retinopathy
- What significant weight loss can mean for the appearance and function of the eyelids
Inside Episode 6
What Is NAION, and What Might You Notice?
NAION stands for non-arteritic anterior ischemic optic neuropathy. It occurs when part of the optic nerve, which carries visual information from the eye to the brain, receives too little blood flow. It can cause a sudden, painless change in vision in one eye, including lasting vision loss.
The hosts ask what that change might feel like at home. You might notice a dark patch or a missing area when you look around. An eye chart measures how well you can see detail straight ahead. Depending on where the affected area is, you may still be able to read the chart while missing part of the scene around it. Sudden vision loss needs immediate medical evaluation, even when there’s no pain. AAO and NANOS consensus statement
Putting the FDA’s Findings in Perspective
In November 2026, the FDA announced that it was requiring safety labeling changes for GLP-1 medications because of a potential increased risk of NAION. In its pooled analysis of 126 clinical trials, the FDA found 6.4 probable cases per 100,000 person-years in the GLP-1 groups and 3.8 in the comparison groups. Fifteen probable cases were identified across both groups. Person-years measure the combined time participants were followed, so these figures describe how often cases occurred across the study groups. FDA safety communication
The hosts ask how much those pooled results can tell us about individual medications such as semaglutide and tirzepatide, and about people taking them for weight loss who don’t have diabetes. They also raise a question researchers face when studying this association. Conditions such as diabetes, high blood pressure, and obstructive sleep apnea are themselves risk factors for NAION. That makes it harder to estimate how much risk a medication might add for any one patient. AAO and NANOS consensus statement
Three Situations Patients May Face
- You take a GLP-1 medication and your vision feels normal. The hosts ask whether the warning calls for an extra eye exam. The American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society advise against routine eye exams solely to assess NAION risk before starting a GLP-1 medication. People with diabetes should continue their scheduled diabetic eye exams.
- You’ve already had NAION in one eye. The episode asks what to discuss with your eye doctor and prescriber before starting or continuing treatment. A history of NAION is relevant to that conversation, alongside the reason for treatment and the benefits you may get from it.
- You suddenly notice a dark patch or loss of vision in one eye. Seek immediate medical evaluation. If you can’t reach your eye doctor promptly, go to an emergency department.
AAO and NANOS guidance on GLP-1 medications and NAION
Why Diabetic Retinopathy Deserves Its Own Conversation
Diabetic retinopathy affects the blood vessels in the retina, the light-sensitive tissue at the back of the eye. In some people who already have diabetic retinopathy, a rapid improvement in blood sugar can temporarily worsen the condition. That possibility matters when planning eye follow-up as diabetes treatment changes. American Academy of Ophthalmology statement on diabetic retinopathy
The hosts put that into practical terms. When was your last dilated eye exam? What did it show? How much has your A1c changed, and who will arrange follow-up? They also ask how the discussion changes for someone taking the medication for weight loss who doesn’t have diabetes.
What Can Change Around the Eyes After Weight Loss?
The episode closes with a question from Dr. Tooley’s area of practice. People sometimes use the phrase “Ozempic face” to describe facial changes after significant weight loss. The hosts narrow the discussion to the area around the eyes and ask what an eyelid specialist looks for when a patient notices a change.
They also ask how an ophthalmologist evaluates eyelid function. Someone may come in because their eyes look different after weight loss. The exam can also explore whether they’re having trouble with how their lids open or close. Those are distinct concerns that patients may bring up at the same visit.
Meet the Wise EYES Guys and Their Guest
Dr. Andrew Holzman is a refractive surgeon and Medical Director of Holzman Laser Vision.
Dr. Jonathan Solomon is a cataract and refractive surgeon whose work includes lens-based vision correction.
Dr. Sonny Goel is a refractive surgeon practicing in the Baltimore region.
Dr. Andrea Tooley is an ophthalmologist who specializes in surgery of the eyelids and eye socket, including complex reconstruction. She has also taught ophthalmology residents at Mayo Clinic.